Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Cogent Biosciences (COGT) Shares Outstanding (2017 - 2026)

Cogent Biosciences' Shares Outstanding history spans 10 years, with the latest figure at $4516.0 for Q1 2026.

  • Quarterly Shares Outstanding fell 100.0% to $4516.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $4516.0 through Mar 2026, down 100.0% year-over-year, with the annual reading at $67414.0 for FY2025, 4.33% down from the prior year.
  • Shares Outstanding came in at $170.8 million for Q1 2026, up from $161.0 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $170.8 million in Q1 2026 to a low of $6868.0 in Q3 2024.
  • The 5-year median for Shares Outstanding is $69.9 million (2022), against an average of $64.6 million.
  • Year-over-year, Shares Outstanding soared 2035829.85% in 2025 and then tumbled 100.0% in 2026.
  • Cogent Biosciences' Shares Outstanding stood at $81050.0 in 2022, then dropped by 8.12% to $74465.0 in 2023, then fell by 5.37% to $70465.0 in 2024, then decreased by 4.33% to $67414.0 in 2025, then crashed by 93.3% to $4516.0 in 2026.
  • Per Business Quant, the three most recent readings for COGT's Shares Outstanding are $4516.0 (Q1 2026), $67414.0 (Q4 2025), and $139.8 million (Q3 2025).